Form 8-K - Current report:
SEC Accession No. 0001493152-24-028669
Filing Date
2024-07-22
Accepted
2024-07-22 15:09:22
Documents
16
Period of Report
2024-07-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40502
2 ex10-1.htm EX-10.1 20595
3 ex10-2.htm EX-10.2 143302
  Complete submission text file 0001493152-24-028669.txt   411806

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE vodg-20240716.xsd EX-101.SCH 3033
5 XBRL LABEL FILE vodg-20240716_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE vodg-20240716_pre.xml EX-101.PRE 22371
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3446
Mailing Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209
Business Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209 8558487627
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

EIN.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41766 | Film No.: 241131265
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)